Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD

Key Takeaways

• FDA cleared Cellenkos’ IND application for Phase 1b/2a trial of CK0802 in steroid-refractory GVHD patients
• CK0802 represents first-in-class, off-the-shelf regulatory T cell therapy targeting tissue-specific treatment
• Multicenter study will evaluate safety and preliminary efficacy in patients who failed standard steroid treatment

---

Cellenkos, Inc. announced May 4, 2026, that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to begin a Phase 1b/2a clinical trial of CK0802 in patients with steroid-refractory graft-versus-host disease (GVHD).

Breakthrough Regulatory T Cell Therapy

The Houston-based clinical-stage biotechnology company is pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies. CK0802 represents a first-in-class, off-the-shelf Treg therapy specifically designed for patients whose GVHD does not respond to standard steroid treatment.

Graft-versus-host disease occurs when transplanted immune cells attack the recipient’s healthy tissues, affecting up to 50% of patients receiving allogeneic stem cell transplants. Current treatment options remain limited, particularly for patients who develop steroid-refractory disease.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Trial Design and Implications

The upcoming multicenter, open-label study will evaluate both safety and preliminary efficacy of CK0802 in this challenging patient population. Unlike traditional approaches, CK0802’s off-the-shelf design could provide immediate treatment availability without requiring patient-specific cell manufacturing.

This FDA clearance positions Cellenkos to address a significant unmet medical need in transplant medicine. Steroid-refractory GVHD carries poor prognosis with limited therapeutic options, making novel approaches like tissue-targeted Treg therapy particularly valuable.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Future Outlook

The regulatory milestone represents a significant advancement in cell therapy development, potentially offering new hope for transplant patients facing treatment-resistant GVHD. The allogeneic approach could provide scalability advantages over autologous cell therapies, potentially reducing treatment costs and improving accessibility.

Cellenkos’ tissue-targeting technology differentiates CK0802 from other Treg therapies in development, potentially improving efficacy while minimizing systemic immunosuppression risks. The Phase 1b/2a trial results will be closely watched by the transplant medicine community and investors tracking the expanding cell therapy market.

---

Frequently Asked Questions

What does this FDA clearance mean for GVHD patients?

The clearance allows Cellenkos to begin testing CK0802 in patients whose GVHD doesn’t respond to steroids, potentially providing a new treatment option for this difficult-to-treat condition.

When will CK0802 be available to patients?

CK0802 is entering Phase 1b/2a trials and would need to complete clinical development and receive FDA approval before becoming commercially available, likely several years away.

How does CK0802 differ from existing GVHD treatments?

CK0802 is a first-in-class, off-the-shelf regulatory T cell therapy that targets specific tissues, unlike current treatments that broadly suppress the immune system.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• MariTide Phase 2 obesity data show up to 20% weight loss at one year
• Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response